Journal of Palliative Care & Medicine

ISSN: 2165-7386

Open Access

The potential application of histamine H3 receptor antagonists in the treatment of several central nervous system illnesses, such as Alzheimer's disease (AD), is presently being investigated. Little is now understood regarding the condition of H3 receptors in AD. Method of experimentation: In the current work, we examined H3 receptor binding in post-mortem human AD brain tissues and the amyloid over-expressing double mutant APPswe ¥ PSI.MI46V (TASTPM) transgenic mouse model of AD using the radiolabelled H3 receptor antagonist [3H]GSK189254.

There were no discernible variations in the particular H3 receptor binding in the brain, hippocampus, or hypothalamus between wild type and TASTPM mice. Sections of human medial frontal cortex from AD brains with varied disease severity (Braak stages) showed specifc [3H]GSK189254 binding 1-VI). We found that,

Keywords:

Introduction

Austin Lynn, School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom, E-mail: austin.l@hotmail.com

27-Dec-2023, Manuscript No. jpcm-23-123055; 29-Dec-2023, PreQC No. jpcm-23-123055(PQ); 12-Jan-2024, QC No. jpcm-23-123055; 18-Jan-2024, Manuscript No. jpcm-23-123055(R); 25-Jan-2024, DOI: 10.4172/2165-7386.1000603

Lynn A (2024) Potential Target for Cognitive Symptoms in Neuropsychiatric Disorders: The Histamine H3 Receptor. J Palliat Care Med 14: 603.

Lynn A (2024) Potential Target for Cognitive Symptoms in Neuropsychiatric Disorders: The Histamine H3 Receptor. J Palliat Care Med 14: 603.





Animals (scientific procedures) Act 1986



Lynn A (2024) Potential Target for Cognitive Symptoms in Neuropsychiatric Disorders: The Histamine H3 Receptor. J Palliat Care Med 14: 603.

Lynn A (2024) Potential Target for Cognitive Symptoms in Neuropsychiatric Disorders: The Histamine H3 Receptor. J Palliat Care Med 14: 603.



6. Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, et al. (2000) Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99: 721-729.

7. Perry E, Court J, Goodchild R, Gri f ths M, Jaros E, et al. (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105: 915-933.

8. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, et al. (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models19. J Pharmacol Exp Ther 321: 1032-1045.

9. Pollard H, Moreau J, Arrang JM, Schwartz JC (1993) A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52: 169-189.

10. Hancock AA, Fox GB (2004) Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13: 1237-1248.

11. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25: 618-625.

12. Witkin JM, Nelson DL (2004) Selective histamine H3 receptor antagonists for treatment of cognitiv